Immune-Mediated Inflammatory Diseases Following Pediatric Uveitis Diagnosis
Authors' conclusion
In this cohort study, children and adolescents with uveitis had an approximately 7-fold increased risk of developing IMIDs compared with the general population, with variation in disease patterns and treatment according to demographic and health care factors.
Study context
- Population
- Children and adolescents younger than 20 years newly diagnosed with uveitis in Korea between 2011 and 202216,827 males [58.3%]
- Participants
- 27,656 children
- Exposure
- Children and adolescents with uveitis vs general pediatric population
- Uveitisn = 27,656
- Outcome
- 5-year cumulative incidence of a composite of 13 predefined IMIDs and age- and sex-adjusted SIRs vs the general pediatric population
- Follow-up
- 5 years
Methodological detailsnationwide health insurance claims data
- Nationwide health insurance claims data
Main finding
As reported in the abstract
Estimated 5-year cumulative incidence of composite immune-mediated inflammatory diseases (IMIDs)
8.52%
95% CI 8.16%–8.87%
Overall SIR for IMIDs vs general pediatric population
6.78
95% CI 6.54–7.02
Observational data: associations, not effects.
Further findings
Most frequent newly diagnosed IMID: AS, cumulative incidence · 5 years
- AS
- 2.53% (95% CI, 2.33%-2.73%)
- Distribution of IMIDs differed across age groups
Disease-specific standardized incidence ratios (SIRs) (highest)
- Sarcoidosis
- 444.48 (95% CI, 357.98-551.89)
- AS
- 68.9 (95% CI, 64.5-73.7)
- BD
- 66.3 (95% CI, 57.8-76.0)
Estimated 5-year incidence of immunosuppressive therapy use by level of care
- Secondary and tertiary care settings
- 8.42% (95% CI, 7.67%-9.16%)
- Primary care settings
- 0.67% (95% CI, 0.55%-0.79%)
- Secondary/tertiary vs primary care
- P < 0.001
- Variation in prescribed agents
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →